TOP 1902- GRID- Advanced NSCLC (Lung Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn more about the study drug (GT-103) and to find the best dose to give to patients with advanced NSCLC.
Advanced Stage Non-Small Cell Lung Cancer
Who Can Participate in the Study?
-Have a diagnosis of advanced non-small cell lung cancer
For more information on who can participate in this study please contact the study team.
What is Involved?
If you choose to join this study, you will:
-Have a physical exam
-Have blood samples taken
-Get the study drug (GT-103) every 3 weeks as long as you continue to do well and tolerate the drug. The study drug will be given into your arm by an IV.
Once you complete your treatment, you will complete a follow-up phone call every 12 weeks for up to 3 years.